Bergenin
Catalog No: CFN98724
Bergenin is a potent antinarcotic agent, has antiviral ,antifungal, antiarrhythmic, antitumor, antiinflammatory, potent immunomodulatory, antitussive, antiulcerogenic,anti-plasmodial, anti-hepatotoxic and wound healing activities. Bergenin has antidiabetic activity, could be classified as a new group of α-glucosidase inhibitors. Bergenin reduces the expression of NO, TNF-α, IL-1β, and IL-6 proinflammatory cytokines by inhibiting the activation of the NF-κB and MAPKs signaling pathways, and it may represent a novel treatment strategy for mastitis.
Taxifolin
Catalog No: CFN98734
Taxifolin exhibits important anti-tyrosinase activity, it also exhibits significant inhibitory activity against collagenase with an IC50 value of 193.3 μM.Taxifolin has anti-oxidant, anti-melanogenic, chemopreventive, anti-inflammatory, and cardioprotective effects. Taxifolin promotes osteoblast differentiation in MC3T3-E1 cells and also inhibit osteoclastogenesis in RAW264.7 cells, it also can enhance andrographolide-induced mitotic arrest and apoptosis in human prostate cancer cells via spindle assembly checkpoint activation.
Naringenin
Catalog No: CFN98742
Naringenin is a weak estrogen that also exhibits partial antiestrogenic activity in the female rat uterus and MCF-7 human breast cancer cells. Naringenin is also a agent for the treatment of hepatitis C virus (HCV) infection. Naringenin has hypocholesterolemic, antioxidant, free radical scavenger, anti-cancer, anti-inflammatory, neuroprotective, carbohydrate metabolism promoter, and immune system modulator properties. Naringenin possesses potent antidepressant-like property via the central serotonergic and noradrenergic systems.
Echinocystic acid
Catalog No: CFN98812
Echinocystic acid has cardioprotective, hypolipidemic, anti-tumor, anti-inflammatory and antioxidant effects, it displays substantial inhibitory activity on HCV entry.Orally administered lancemaside A may be metabolized to echinocystic acid, which may be absorbed into the blood and ameliorate memory and learning deficits by inhibiting AChE activity and inducing BDNF and p-CREB expressions.Orally administered lancemaside A may be metabolized to echinocystic acid, which may be absorbed into the blood and ameliorate memory and learning deficits by inhibiting AChE activity and inducing BDNF and p-CREB expressions.
